Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vaxcyte, Inc. (Nasdaq: PCVX) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage vaccine innovation company developing broad-spectrum conjugate and novel protein vaccines against bacterial diseases, Vaxcyte uses its SEC reports to communicate financial results, material agreements and key milestones for its pneumococcal conjugate vaccine (PCV) franchise and broader pipeline.
Investors can review Form 8-K current reports in which Vaxcyte furnishes press releases on quarterly financial results, clinical and regulatory updates, and significant contracts. For example, recent 8-K filings reference earnings announcements and a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific, under which Patheon will formulate, fill, package, label, test, manufacture and supply drug product for Vaxcyte at a facility in Greenville, North Carolina. These filings outline key commercial supply arrangements, binding minimum order commitments, term length and termination provisions.
In addition to 8-Ks, users can expect to find Vaxcyte’s periodic reports such as Form 10-Q and Form 10-K (when available), which typically include detailed discussions of the company’s PCV programs (VAX-31, VAX-24 and VAX-XL), early-stage candidates like VAX-A1 and VAX-GI, use of the XpressCF cell-free protein synthesis platform, risk factors and liquidity information. These documents help explain how Vaxcyte is prioritizing resources for its PCV franchise, its capital position and its manufacturing investments.
Stock Titan’s interface is designed to surface new Vaxcyte filings in near real time as they appear on EDGAR and to pair them with AI-generated summaries that highlight the sections most relevant to shareholders, such as clinical program updates, material agreements, and changes in strategy. Users can also look for Form 4 and related ownership filings to monitor insider transactions when they are reported. Together, these filings offer a structured view of how Vaxcyte is advancing its pneumococcal and bacterial vaccine programs from both a scientific and corporate perspective.
Vaxcyte, Inc. chief operating officer Jim Wassil reported an open-market sale of 2,250 shares of common stock at a weighted-average price of $56.831 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. After this sale, he directly holds 160,744 shares of Vaxcyte common stock.
PCVX insider reported planned sales of company common stock. The filing lists two sale notices: 7,395 shares for $435,438.31 dated 03/10/2026 and 2,250 shares for $131,475.60 dated 04/01/2026, totaling $566,913.91. The filing also lists recent issuer vesting events (RSU and ESPP) with specified share counts and vesting dates.
Vanguard Capital Management reported beneficial ownership of 7,252,053 shares of Vaxcyte Inc. common stock, representing 5.03% of the class. The filing shows Vanguard has sole power to dispose of 7,252,053 shares and sole voting power over 985,352 shares. The filing is signed by Ashley Grim on 04/30/2026.
Vaxcyte, Inc. is holding its 2026 virtual Annual Meeting on June 15, 2026 at 8:30 a.m. Pacific Time. Stockholders of record as of April 20, 2026, when 144,387,225 common shares were outstanding, may vote online or by proxy.
Stockholders will vote on three items: electing three Class III directors to serve until the 2029 meeting, ratifying Deloitte & Touche LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The Board recommends voting in favor of all three proposals.
The filing details Vaxcyte’s governance structure, including a majority‑independent board, fully independent key committees, and formal risk‑oversight responsibilities. It also highlights stock ownership guidelines, restrictions on hedging and pledging, and a director pay program combining cash retainers with annual equity grants and change‑in‑control vesting.
The Compensation Committee notes that only 64% of votes supported the 2025 say‑on‑pay proposal, describes extensive outreach to major investors, and commits to limiting one‑time executive equity awards to extraordinary, well‑justified situations while emphasizing ongoing pay‑for‑performance alignment.
Vaxcyte, Inc. SVP, Finance & CAO Elvia Cowan exercised stock options and then sold the resulting shares. On 2026-04-07, she exercised options for 3,000 shares of common stock at an exercise price of $25.92 per share and acquired 3,000 shares.
The same day, she sold 3,000 shares of common stock at $60.00 per share in an open-market transaction, leaving her with 28,975 shares held directly after the sale. The filing notes that the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025, indicating the transactions were scheduled in advance.
Elvia Cowan filed a Form 144 reporting the proposed sale of 3,000 shares of Common Stock on 04/07/2026, attributed to an exercise of stock options with cash payment. The filing also lists prior sales: 2,500 shares on 03/11/2026 for $146,481.75 and 1,892 shares on 03/17/2026 for $105,146.20.
Vaxcyte, Inc. chief operating officer Jim Wassil reported open-market sales of 2,250 shares of common stock. On April 1, 2026, he sold 1,412 shares at a weighted-average price of $58.138 and 838 shares at a weighted-average price of $58.932.
After these sales, he directly owned 162,994 shares of Vaxcyte common stock. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025. A footnote also describes prior share transfers to his ex-spouse pursuant to a divorce settlement domestic relations order.
PCVX reported a resale transaction. James Wassil sold 7,395 shares of Common Stock on 03/10/2026 for $435,438.31, as shown on the notice filed by UBS Financial Services, Inc. The filing also lists RSU vesting amounts of 783 and 1,467 shares with vest dates in 2025.
Vaxcyte Inc Schedule 13G/A shows The Vanguard Group reporting 0 shares beneficially owned and 0% of the common stock following an internal realignment. The filing states certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538, and was signed on 03/27/2026.